Thelansis

  Pulmonary arterial hypertension (PAH) is a chronic and progressive disorder characterized by antiproliferative vasculopathy in the pulmonary arterioles, leading to endothelial and smooth muscle proliferation and dysfunction, inflammation, and thrombosis. ·        As per Thelansis’ research, the total prevalent cases of Pulmonary Arterial Hypertension (PAH) in 8 major markets ranges from 129,857 in 2018 to 148,655 by 2030. Idiopathic PAH is the most commonly found form of Pulmonary Arterial Hypertension (PAH). Higher Prevalence of Pulmonary Arterial Hypertension is observed among females as compared to males in 8MM countries ·        Among the diseases associated with PAH, it was observed by the Thelansis research team that around ~50% of patients are associated with Connective Tissue Disease (CTD), and ~19% have Congenital Heart Disease (CHD), and ~11% suffer from portal hypertension ·     ...